In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Current state of cardiovascular secondary prevention in patients with stable coronary heart disease: the Czech EUROASPIRE V Study.

Session Poster Session 2

Speaker Associate Professor Jan Bruthans

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P524

Authors : J Bruthans (Prague,CZ), O Mayer (Pilsen,CZ), P Sulc (Prague,CZ), J Mlikova Seidlerova (Pilsen,CZ), J Vanek (Pilsen,CZ)

Authors:
J Bruthans1 , O Mayer2 , P Sulc1 , J Mlikova Seidlerova2 , J Vanek2 , 1First Faculty of Medicine, Charles University and Thomayer Hospital, Center for Cardiovascular Prevention - Prague - Czechia , 2Faculty of Medicine Pilsen, Charles University, 2nd Department of Medicine - Pilsen - Czechia ,

On behalf: EUROASPIRE V

Citation:

Aim: 
The aim of the presented study was to evaluate, how, in clinical practice, the current coronary heart disease (CHD) secondary prevention guidelines are implemented and to compare the data in Europen context and in time queue. Specific attention was attained to impaired glycid metabolism.

Methods and patient sample: 
Men and women < 80 years, from Prague 4 and Pilsen region, hospitalized for acute coronary syndrome and/or catheter or surgery revascularization at one Institute or our faculty, were retrospectively identified. Patients data were obtained from hospitalization reports and from subsequent outpatient investigation carried 6 - 24 months after hospitalization (anthropomety, medical investigation, structered questioneeres, blood samples analysis, oral glucose tolerance test (OGTT) and further investigations). The study was a part of the repeated European study (this one in 27 countries and 131 centers) following the protocol of the EUROASPIRE V study.

Results: 
624 patients were identified, 406 respondents investigated.  20% of patients continued to smoke after the index hospitalization.  44,8% were obese (BMI > 30), overweight and obese (BMI > 25)  were 85,5% of respondents, centraly obese (waist circumference= 102 cm in men,  = 88 cm in women) were 71,4%. Blood pressure raised above the goals of recent guidelines (BP < 140/90 mmHg and < 140/80 mmHg in patients with diabetes) had 55,1% of patients, in those treated for hypertension the recommended level of blood pressure was achieved in 38,9% only. LDL cholesterol increased obove the recommended goals (>1,8mmol/l) had 63,5% of patients. 93,1% were treated by hypolipidemics, but only  38,6% of them achieved the recommended LDL level. Diabetes (the known and the newly diagnosed (also by OGTT) we found in 48,4% respondents. Only minor part of patients adhered to the life style secondary prevention recommendations, namely to recommended physical activity.

Conclusions:
In patients in secondary CHD prevention prevalence of obesity and diabetes further increased. Pharmacotherapy is used in major part of patients, but in more than half of the patients the recommended goals of blood pressure, lipid and glycid metabolism are not achieved. The control of blood pressure, compared to previous survey, was even worse. This is due to insufficiently high drug dosage and insufficient patient compliance. Implementation of  healthy life style remains unsatisfactory. Compared to European average data the obesity, diabetes and insufficient physical activity prevalence is considerably higher in this high risk Czech population.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are